Mahwash Mukhtar

Dr. Mahwash Mukhtar

Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Faculty of Pharmacy, Szeged, Csongrád, Hungary
orcid
Open for collaboration in macrophage targeted drug delivery

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2020 in Chemosensors
Verified
Journal Article
Open access
PDF file
Mahwash MukhtarMahwash Mukhtar
Mahwash Mukhtar
MQM Qammar
M Qammar
Abbas RahdarAbbas Rahdar
Abbas Rahdar
Mahmood BaraniMahmood Barani
Mahmood Barani
Rabia ArshadRabia Arshad
Rabia Arshad
Simona BungăuSimona Bungău
Simona Bungău
Brain tumors, especially glioblastoma, remain the most aggressive form of all the cancers because of inefficient diagnosis and profiling. Nanostructures, such as metallic nanostructures, silica nano-vehicles, quantum dots, lipid nanoparticles (NPs) and polymeric NPs, with high specificity have made it possible to permeate the blood–brain barrier (BBB). NPs possess optical, magnetic and photodynamic properties that can be exploited by surface modification, bio composition, contrast agents’ encapsulation and coating by tumor-derived cells. Hence, nanotechnology has brought on a revolution in the field of diagnosis and imaging of brain tumors and cancers. Recently, nanomaterials with biomimetic functions have been introduced to efficiently cross the BBB to be engulfed by deep skin tumors and cancer malignancies for imaging. The review focuses on nanotechnology-based diagnostic and imaging approaches for exploration in brain tumors and cancers. Moreover, the review also summarizes a few strategies to image glioblastoma and cancers by multimodal functional nanocomposites for more precise and accurate clinical diagnosis. Their unique physicochemical attributes, including nanoscale sizes, larger surface area, explicit structural features and ability to encapsulate diverse molecules on their surface, render nanostructured materials as excellent nano-vehicles to cross the blood–brain barrier and convey drug molecules to their target region. This review sheds light on the current progress of various kinds of nanomaterials, such as liposomes, nano-micelles, dendrimers, carbon nanotubes, carbon dots and NPs (gold, silver and zinc oxide NPs), for efficient drug delivery in the treatment and diagnosis of brain cancer.

20 February 2021 in Biosensors
Verified
Journal Article
Open access
PDF file
Mahmood BaraniMahmood Barani
Mahmood Barani
Mahwash MukhtarMahwash Mukhtar
Mahwash Mukhtar
Abbas RahdarAbbas Rahdar
Abbas Rahdar
Saman SargaziSaman Sargazi
Saman Sargazi
SPSadanand Pandey
Sadanand Pandey
Misook   KangMisook Kang
Misook Kang
Osteosarcoma (OSA) is a type of bone cancer that begins in the cells that form bones. OSA is a rare mesenchymal bone neoplasm derived from mesenchymal stem cells. Genome disorganization, chromosomal modifications, deregulation of tumor suppressor genes, and DNA repair defects are the factors most responsible for OSA development. Despite significant advances in the diagnosing and treatment of OSA, patients’ overall survival has not improved within the last twenty years. Lately, advances in modern nanotechnology have spurred development in OSA management and offered several advantages to overcome the drawbacks of conventional therapies. This technology has allowed the practical design of nanoscale devices combined with numerous functional molecules, including tumor-specific ligands, antibodies, anti-cancer drugs, and imaging probes. Thanks to their small sizes, desirable drug encapsulation efficiency, and good bioavailability, functionalized nanomaterials have found wide-spread applications for combating OSA progression. This review invokes the possible utility of engineered nanomaterials in OSA diagnosis and treatment, motivating the researchers to seek new strategies for tackling the challenges associated with it.

2 January 2021 in Molecules
Verified
Journal Article
Open access
PDF file
Mahmood BaraniMahmood Barani
Mahmood Barani
Mahwash MukhtarMahwash Mukhtar
Mahwash Mukhtar
Abbas RahdarAbbas Rahdar
Abbas Rahdar
Ghasem SargaziGhasem Sargazi
Ghasem Sargazi
ATANNA THYSIADOU
ANNA THYSIADOU
George Z. KyzasGeorge Z. Kyzas
George Z. Kyzas
The blood–brain barrier (BBB) is the protective sheath around the brain that protects the sensitive microenvironments of the brain. However, certain pathogens, viruses, and bacteria disrupt the endothelial barrier and cause infection and hence inflammation in meninges. Macromolecular therapeutics are unable to cross the tight junctions, thereby limiting their bioavailability in the brain. Recently, nanotechnology has brought a revolution in the field of drug delivery in brain infections. The nanostructures have high targeting accuracy and specificity to the receptors in the case of active targeting, which have made them the ideal cargoes to permeate across the BBB. In addition, nanomaterials with biomimetic functions have been introduced to efficiently cross the BBB to be engulfed by the pathogens. This review focuses on the nanotechnology-based drug delivery approaches for exploration in brain infections, including meningitis. Viruses, bacteria, fungi, or, rarely, protozoa or parasites may be the cause of brain infections. Moreover, inflammation of the meninges, called meningitis, is presently diagnosed using laboratory and imaging tests. Despite attempts to improve diagnostic instruments for brain infections and meningitis, due to its complicated and multidimensional nature and lack of successful diagnosis, meningitis appears almost untreatable. Potential for overcoming the difficulties and limitations related to conventional diagnostics has been shown by nanoparticles (NPs). Nanomedicine now offers new methods and perspectives to improve our knowledge of meningitis and can potentially give meningitis patients new hope. Here, we review traditional diagnosis tools and key nanoparticles (Au-NPs, graphene, carbon nanotubes (CNTs), QDs, etc.) for early diagnosis of brain infections and meningitis.

30 March 2021 in Chemosensors
Verified
Journal Article
Open access
PDF file
Fakhara SabirFakhara Sabir
Fakhara Sabir
Mahmood BaraniMahmood Barani
Mahmood Barani
Mahwash MukhtarMahwash Mukhtar
Mahwash Mukhtar
Abbas RahdarAbbas Rahdar
Abbas Rahdar
Magali CucchiariniMagali Cucchiarini
Magali Cucchiarini
Simona BungăuSimona Bungău
Simona Bungău
Cardiovascular diseases (CVDs) are the world’s leading cause of mortality and represent a large contributor to the costs of medical care. Although tremendous progress has been made for the diagnosis of CVDs, there is an important need for more effective early diagnosis and the design of novel diagnostic methods. The diagnosis of CVDs generally relies on signs and symptoms depending on molecular imaging (MI) or on CVD-associated biomarkers. For early-stage CVDs, however, the reliability, specificity, and accuracy of the analysis is still problematic. Because of their unique chemical and physical properties, nanomaterial systems have been recognized as potential candidates to enhance the functional use of diagnostic instruments. Nanomaterials such as gold nanoparticles, carbon nanotubes, quantum dots, lipids, and polymeric nanoparticles represent novel sources to target CVDs. The special properties of nanomaterials including surface energy and topographies actively enhance the cellular response within CVDs. The availability of newly advanced techniques in nanomaterial science opens new avenues for the targeting of CVDs. The successful application of nanomaterials for CVDs needs a detailed understanding of both the disease and targeting moieties.

29 July 2019 in Nanomedicine
Verified
Journal Article
Closed access
MZMahira Zeeshan
Mahira Zeeshan
HAHussain Ali
Hussain Ali
SKSalman Khan
Salman Khan
Mahwash MukhtarMahwash Mukhtar
Mahwash Mukhtar
Muhammad Ijaz Khan KhattakMuhammad Ijaz Khan Khattak
Muhammad Ijaz Khan Khattak
MAMuhammad Arshad
Muhammad Arshad
Aim: To fabricate and evaluate the therapeutic efficacy of glycyrrhizic acid (GA)-loaded pH-sensitive nanoformulations that specifically target and combat mucosal inflammation of the colon. Methods: GA-loaded Eudragit® S100/poly-(lactic-co-glycolic acid) nanoparticles were developed through modified double-emulsion evaporation coupled with solvent evaporation coating techniques and analyzed for physicochemical characteristics, surface chemistry, release kinetics, site-retention and therapeutic effectiveness. Results: Nanoparticles have a particle size of approximately 200 nm, high encapsulation efficiency, desired surface chemistry with pH-dependent and sustained drug release behavior following the Gompertz kinetic model. In vivo retention and therapeutic effectiveness in the inflamed colon tissues were confirmed by macroscopic and microscopic indices, cytokine analysis and antioxidant assays. Conclusion: GA-loaded Eudragit S100/poly-(lactic-co-glycolic acid) nanoparticles could efficiently deliver GA to the colon and ameliorate the mucosal inflammation for a prolonged duration.

29 June 2020 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
Mahwash MukhtarMahwash Mukhtar
Mahwash Mukhtar
HAHussain Ali
Hussain Ali
NANaveed Ahmed
Naveed Ahmed
RMRashid Munir
Rashid Munir
STSumbal Talib
Sumbal Talib
Rita AmbrusRita Ambrus
Rita Ambrus
Macrophages are involved in the normal defense of the body; however, the varying phenotypes of macrophages and imbalance in their ratio lead to the impairment of immune response initiating the prod...